scholarly journals Endoscopic retrograde cholangiopancreatography for treatment of choledocholithiasis with ectopic duodenal papilla

2015 ◽  
Vol 23 (27) ◽  
pp. 4423
Author(s):  
Yun-Xiao Liang ◽  
Bing Nong ◽  
Lie-Xin Liang
Digestion ◽  
2015 ◽  
Vol 91 (1) ◽  
pp. 42-45 ◽  
Author(s):  
Haruka Fujinami ◽  
Shinya Kajiura ◽  
Takayuki Ando ◽  
Hiroshi Mihara ◽  
Ayumu Hosokawa ◽  
...  

2021 ◽  
Vol 49 (8) ◽  
pp. 030006052110351
Author(s):  
Hui Liu ◽  
Chun-Meng Jiang ◽  
Bo Qu ◽  
Zhi-Guo Wang

Endoscopic retrograde cholangiopancreatography is widely used in the diagnosis and treatment of pancreatobiliary diseases; however, successful biliary cannulation is a prerequisite for this operation. We herein present a new method in a patient in whom cannulation was difficult. A 56-year-old man was admitted to the hospital with choledocholithiasis. Endoscopic retrograde cholangiopancreatography was performed, and duodenoscopy revealed that the patient’s duodenal papilla was located at the initial part of the horizontal segment of the duodenum. Because of the ectopic location of the duodenal papilla, the guidewire could not be inserted into the biliary and pancreatic duct. Therefore, we performed a new method to resolve the problem of difficult cannulation. A polypectomy snare was used to excise the mucosa covering the surface of the intramural segment of the common bile duct, and a dual knife was used to form a fistula. A guidewire was then inserted through the stoma into the bile duct. After the procedure, the bile duct was successfully cannulated and the stones were removed. No complications occurred. This new method may be an alternative treatment to precutting for difficult biliary cannulation in patients with a protruded papilla of Vater.


2020 ◽  
Vol 1 (30) ◽  
pp. 30-36
Author(s):  
E. A. Krylova ◽  
D. V. Aleinik

The article presents the results of a study of the effectiveness of the use of an inhibitor of pancreatic enzyme secretion of octreotide (Octrade) for the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). It was shown that the administration of Octrade at a dose of 0.3 mg in 500 ml of 0.9 % NaCl by continuous intravenous infusion for 7 hours and then 0.1 mg of Octrade subcutaneously at 6 and 12 hours after the end of intravenous infusion significantly reduced the frequency of pancreatitis (4.0 % and 22.2 %; p < 0.05) and hyperamylasemia (8.0 % and 25.9 %; p < 0.05) after ERCP. It is concluded that Octrade is effective in preventing the development of pancreatitis and hyperamilasemia after ERCP.


Sign in / Sign up

Export Citation Format

Share Document